{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:52:30Z","timestamp":1791647550823,"version":"4.3.4"},"reference-count":33,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Karyopharm Therapeutic Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Treatment for relapsed\/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens. Real-world studies can help to determine the optimal treatment sequences and dosing through observed usage of drugs outside of clinical trials. Previous clinical trials have demonstrated high rates of durable responses in the treatment of patients with triple-class-exposed RRMM with regimens containing selinexor, a first-in-class, orally available selective exportin 1 inhibitor. This study analyzed real-world treatment patterns and survival outcomes using a nationwide electronic health record-derived, deidentified database of patients with RRMM treated with an eligible selinexor-containing, triplet-based regimen, including combinations with dexamethasone and pomalidomide, bortezomib, carfilzomib, or daratumumab. Patients had a real-world overall survival (rwOS) of 14.7 months (95% CI: 10.6, 20.9) and a derived progression-free survival (dPFS) of 4.7 months (95% CI: 3.4, 6.7). Patients with previous exposure to anti-CD38 monoclonal antibodies (mAbs) in the most recent regimen prior to the selinexor treatment had numerically higher survival outcomes (rwOS, 20.9; dPFS, 8.7 months). These data suggest that, in the real-world setting, the use of selinexor triplet regimens is effective in patients with RRMM, especially those with prior exposure to an anti-CD38 mAb in the immediate prior line of therapy.<\/jats:p>","DOI":"10.3390\/curroncol32050268","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:44:23Z","timestamp":1746171863000},"page":"268","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed\/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen"],"prefix":"10.3390","volume":"32","author":[{"given":"Andrew","family":"Whiteley","sequence":"first","affiliation":[{"name":"Texas Oncology-Baylor Sammons Cancer Center, 3410 Worth Street, Suite 400, Dallas, TX 75246, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5270-0832","authenticated-orcid":false,"given":"Stephen C.","family":"Ijioma","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Newton, MA 02459, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ray","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Newton, MA 02459, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer S.","family":"Langerman","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc., New York, NY 10013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Hu","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc., New York, NY 10013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Pierre","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc., New York, NY 10013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Mark","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Newton, MA 02459, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habte","family":"Yimer","sequence":"additional","affiliation":[{"name":"Texas Oncology-Tyler, Tyler, TX 75702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10080","DOI":"10.1016\/j.blre.2021.100808","article-title":"Improving outcomes for patients with relapsed multiple myeloma","volume":"49","author":"Ramasamy","year":"2021","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17425255.2019.1621839","article-title":"Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma","volume":"15","author":"Baljevic","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.3390\/curroncol29070355","article-title":"Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies","volume":"29","author":"Stalker","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment Options for Triple-class Refractory Multiple Myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_18","first-page":"1","article-title":"Treatment Options for Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma","volume":"20","author":"Dimopoulos","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-World Evidence: A Primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharm. Med. Adis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Reiman","year":"2023","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/0008-5472.CAN-24-0886","article-title":"The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma","volume":"85","author":"Sudalagunta","year":"2024","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.clml.2023.06.001","article-title":"Selinexor-Based Triplet Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclon Antibodies","volume":"23","author":"Schiller","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","unstructured":"Birnbaum, B., Nussbaum, N., Seidl-Rathkopf, K., Agrawal, M., Estevez, M., Estola, E., SHaimson, J., He, L., Larson, P., and Richardson, P. (2020). Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ma, X., Long, L., Moon, S., Adamson, B.J.S., and Baxi, S.S. (2020). Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR. Medrxiv.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1182\/blood-2024-199224","article-title":"Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ackerman, B., Gan, R.W., Meyer, C.S., Wang, J.R., Zhang, Y., Hayden, J., Mahoney, G., Lund, J.L., Weberpals, J., and Schneeweiss, S. (2024). Measurement Error and Bias in Real-World Oncology Endpoints when Constructing External Control Arms. Front. Drug Saf. Regul., 4.","DOI":"10.3389\/fdsfr.2024.1423493"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.26010","article-title":"Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH","volume":"96","author":"Cornell","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"White, D., Schiller, G.J., Madan, S., Lentzsch, S., Chubar, E., Lavi, N., Van Domelen, D.R., Bentur, O.S., and Baljevic, M. (2024). Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1352281"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Binder, A.F., Walker, C.J., Mark, T.M., and Baljevic, M. (2023). Impacting T-cell fitness in multiple myeloma: Potential roles for selinexor and XPO1 inhibitors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1275329"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International Myeloma Working Group Immunotherapy Committee Recommendation on Sequencing Immunotherapy for Treatment of Multiple Myeloma: Multiple myeloma, gammopathies","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/268\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:26:20Z","timestamp":1760030780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["curroncol32050268"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32050268","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}